• Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • About
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Advertise
PharmaLive
  • Marketing & Advertising
  • R&D
  • Therapeutics
  • Resources
  • Manny Awards
  • Events
  • Issue Archives
  • Subscribe
  • Search
  • Menu

Teva proposes $5B settlement for thousands of opioid lawsuits

Business, Therapeutics

Teva proposes $5B settlement for thousands of opioid lawsuits

Published: Jul 27, 2022

By Tristan Manalac

BioSpace

In its second quarter financial report this year, Teva Pharmaceuticals announced that it had arrived at an almost $5-billion settlement for thousands of pending opioid liability lawsuits.

The agreement, pending participation by states and subdivisions, will see the Tel-Aviv, Israel-based company pay $3.7 billion in cash to states and other local government units over a 13-year period and shoulder all lawyer fees incurred by the plaintiffs. Under the terms of the proposed settlement, Teva will also provide $1.2-billion worth of the generic version of Narcan (naloxone hydrochloride nasal spray), a drug to reverse opioid overdose, spread over 10 years.

Courtesy of BioSpace

Teva expects to finalize and complete the documentation needed for the proposal in the coming weeks, followed by a nationwide sign-on process for states, subdivisions and Native American tribes. If agreed upon by enough plaintiffs, the settlement would resolve most opioid-related cases against Teva. Except for the potential relief phase of a New York litigation, no remaining trials are scheduled for the rest of the year.

The company maintains that its settlement does not constitute an admission of wrongdoing, insisting that it is only in its best interest to move past the lawsuits to better serve their patients.

Teva’s proposal is also contingent on settlements by Allergan, whose opioid generics Teva bought in 2016. Pharma giant AbbVie acquired Allergan in 2019. Allergan must reach its nationwide settlement for Teva’s to push through. The two companies must also agree on how much Allergan owes Teva for claims filed before the 2016 acquisition.

News about Teva’s plans to settle first surfaced in May, when a Bloomberg report cited three unnamed sources who knew that both Teva and AbbVie were willing to fork over a combined $5 billion to quiet the lawsuits. At the time, it was still unclear how much each company was contributing to the sum, but Teva chief executive officer Kare Schultz pegged Teva’s share to be at around $2.6 billion in cash and medicine.

These opioid lawsuits have long been a painful thorn in Teva’s side. In March 2019, New York Attorney General Letitia James filed what her office called the “nation’s most comprehensive suit against opioid distributors and manufacturers.” Among the defendants were Teva and Allergan, which was already under AbbVie at the time.

The charge was that these companies engaged in years of deceptive marketing and were remiss in their duties to monitor the large-scale diversion of opioid substances—and that they were all ultimately responsible for the opioid crisis in the state. Nearly three years later, in December 2021, a New York jury found Teva guilty of misleading people about the dangers of opioids, in a ruling that could set the company back by more than $1.5 billion. Teva said that it would appeal the decision.

Earlier this month, NY Attorney General James continued her rally against Teva and revealed evidence that the Israel-based parent company, not just its United States unit, intentionally misrepresented its role in the opioids industry in the U.S. “to evade legal action and accountability.”

Teva’s legal woes go far beyond New York, too. In March this year, the company and AbbVie settled opioid-related lawsuits in Rhode Island for a total of $28.5 million. In September last year, the company surrendered $15 million to the state of Louisiana for similar cases.

Source: BioSpace

July 27, 2022/by BioSpace
Tags: AbbVie, Allergan, lawsuits, opioid crisis, opioid deaths, opioid epidemic, opioid liability, Teva Pharmaceutical
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail
https://www.pharmalive.com/wp-content/uploads/2022/07/BioSpacegavelpills7-27-2022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-07-27 09:48:012022-07-27 09:48:01Teva proposes $5B settlement for thousands of opioid lawsuits
You might also like
AbbVie AbbVie's migraine drug scores another Phase III win
U.S. Supreme Court takes no action on Bayer bid to nix weedkiller suits
AbbVie Despite $2B AML Deal, AbbVie Stops Early Cancer Combo Trial With I-Mab
Teva Teva lied about opioid role, New York says
J&J unit files for second bankruptcy to pursue $8.9 billion talc settlement
FDA sign FDA approves first nasal Nalmefene spray for opioid overdose
J&J Cancer victims urge court to end J&J bankruptcy roadblock to lawsuits
RocheReuters Roche's cancer therapy gets US FDA nod, heating up competition with AbbVie
Recent
  • Citrus Health GroupCitrus Health Group acquires Medlogix CommunicationsSeptember 25, 2023 - 9:52 am
  • Scynexis to recall GSK-partnered antifungal from marketSeptember 25, 2023 - 8:55 am
  • Novo Nordisk and Valo to research cardiometabolic treat...September 25, 2023 - 8:49 am
  • FDAReutersFDA staff reviewers raise concerns over BrainStorm Cell’s...September 25, 2023 - 8:38 am
Popular
  • Citrus Health GroupCitrus Health Group acquires Medlogix CommunicationsSeptember 25, 2023 - 9:52 am
  • M&A, Partnerships And CollaborationsJanuary 1, 2011 - 1:48 pm
  • OTC Review And OutlookMarch 9, 2011 - 4:17 pm
  • Global Contract Manufacturing Companies: Pharmaceutical...November 11, 2011 - 3:31 pm
Tags
AbbVie acquisition Alzheimer's disease artificial intelligence AstraZeneca Biogen BioNTech Bristol-Myers Squibb cancer China clinical trial clinical trials Covid-19 COVID-19 pandemic Drug development Eli Lilly European Union FDA gene therapy GSK healthcare communications healthcare marketing Johnson & Johnson lawsuit leadership Med Ad News Merck Moderna monkeypox Novartis Novo Nordisk Oncology pandemic patient access patient safety people on the move Pfizer rare disease regulatory approval Roche Sanofi supply chain U.S. Food and Drug Administration (FDA) United States World Health Organization
© Copyright - PharmaLive and Outcomes LLC | Designed by Joe Lumi LLC
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
Ogilvy Health Bolsters Executive Leadership Team, Recruiting Tyler Montague... Tyler Montague, Ogilvy Health Monkeypox testing Fire Island Monkeypox emergency could last months, with window closing to stop spread, experts...
Scroll to top
PharmaLive

X